Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.

[1]  S. Suissa,et al.  Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study , 2021, COPD.

[2]  Yaa-Hui Dong,et al.  Comparative Safety and Effectiveness of Inhaled Corticosteroids and Long-Acting β2 Agonist Combinations in Patients with Chronic Obstructive Pulmonary Disease. , 2019, Chest.

[3]  S. Suissa,et al.  Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD , 2019 .

[4]  Jessica M Franklin,et al.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.

[5]  S. Suissa,et al.  Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. , 2019, Chest.

[6]  Darren Lunn,et al.  Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum , 2019, International journal of epidemiology.

[7]  J. Castellsagué,et al.  GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD) , 2019, Pharmacoepidemiology and drug safety.

[8]  S. Suissa,et al.  Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. , 2018, The Lancet. Respiratory medicine.

[9]  S. Rennard,et al.  Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. , 2018, The Lancet. Respiratory medicine.

[10]  I. Pavord,et al.  Eosinophils in COPD: just another biomarker? , 2017, The Lancet. Respiratory medicine.

[11]  K. Rothnie,et al.  Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care , 2017, International journal of chronic obstructive pulmonary disease.

[12]  S. Suissa,et al.  Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events , 2017, European Respiratory Journal.

[13]  S. Suissa,et al.  Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores , 2017, Pharmacoepidemiology and drug safety.

[14]  L. Smeeth,et al.  Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records , 2016, Clinical epidemiology.

[15]  L. Smeeth,et al.  Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records , 2016, PloS one.

[16]  I. Pavord,et al.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.

[17]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[18]  C. Strange,et al.  Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study , 2015, Respiratory Research.

[19]  L. Smeeth,et al.  Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD) , 2014, BMJ Open.

[20]  S. Suissa,et al.  Inhaled corticosteroids in COPD and the risk of serious pneumonia , 2013, Thorax.

[21]  C. Janson,et al.  Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study , 2013, Journal of internal medicine.

[22]  C. Janson,et al.  Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) , 2013, BMJ.

[23]  Brian Sauer,et al.  The incident user design in comparative effectiveness research , 2013, Pharmacoepidemiology and drug safety.

[24]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[25]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[26]  Joshua P Metlay,et al.  Accuracy of pneumonia hospital admissions in a primary care electronic medical record database , 2012, Pharmacoepidemiology and drug safety.

[27]  F. Radner,et al.  Risks of pneumonia in patients with asthma taking inhaled corticosteroids. , 2011, American Journal of Respiratory and Critical Care Medicine.

[28]  C. Blanchette,et al.  Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management , 2011, Journal of medical economics.

[29]  L. Blais,et al.  Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication , 2010, Clinical therapeutics.

[30]  L. Smeeth,et al.  Validation and validity of diagnoses in the General Practice Research Database: a systematic review , 2010, British journal of clinical pharmacology.

[31]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[32]  Corri Black,et al.  Validity of the General Practice Research Database , 2003, Pharmacotherapy.

[33]  S. Suissa,et al.  Long‐Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population‐Based Comparative Safety Study , 2017, Chest.

[34]  P. Calverley,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.